Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Combination with metformin  





2 Adverse effects  





3 See also  





4 References  





5 External links  














Vildagliptin






Dansk
Deutsch
Español
فارسی
Français
Italiano
Nederlands

Oʻzbekcha / ўзбекча
Português
Română
Русский
Српски / srpski
Srpskohrvatski / српскохрватски

 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Vildagliptin
Skeletal formula
Ball-and-stick model
Clinical data
Trade namesGalvus, Zavamet others
Other namesLAF237
AHFS/Drugs.comUK Drug Information
License data
Pregnancy
category
  • Not recommended
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
  • EU: Rx-only
  • In general: ℞ (Prescription only)
  • Pharmacokinetic data
    Bioavailability85%
    Protein binding9.3%
    MetabolismMainly hydrolysis to inactive metabolite; CYP450 not appreciably involved
    Elimination half-life2 to 3 hours
    ExcretionKidney
    Identifiers
    • (S)-1-[N-(3-Hydroxy-1-adamantyl)glycyl]pyrrolidine-2-carbonitrile

    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.158.712 Edit this at Wikidata
    Chemical and physical data
    FormulaC17H25N3O2
    Molar mass303.406 g·mol−1
    3D model (JSmol)
    Solubility in waterFreely Soluble in water mg/mL (20 °C)
    • N#C[C@H]4N(C(=O)CNC13CC2CC(C1)CC(O)(C2)C3)CCC4

    • InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1 checkY

    • Key:SYOKIDBDQMKNDQ-XWTIBIIYSA-N checkY

     ☒NcheckY (what is this?)  (verify)

    Vildagliptin, sold under the brand name Galvus and others, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1[2][3] and GIP[3] by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.

    It was approved by the EMA in 2007.[4]

    Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.[2]

    Combination with metformin[edit]

    The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral treatment for type-2 diabetes.[5]

    Adverse effects[edit]

    Adverse effects observed in clinical trials include nausea, hypoglycemia, tremor, headache and dizziness. Rare cases of hepatoxicity have been reported.[6]

    There have been case reports of pancreatitis associated with DPP-4 inhibitors. A group at UCLA reported increased pre-cancerous pancreatic changes in rats and in human organ donors who had been treated with DPP-4 inhibitors.[7][8] In response to these reports, the United States FDA and the European Medicines Agency each undertook independent reviews of all clinical and preclinical data related to the possible association of DPP-4 inhibitors with pancreatic cancer. In a joint letter to the New England Journal of Medicines, the agencies stated that "Both agencies agree that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with the current data. The FDA and the EMA have not reached a final conclusion at this time regarding such a causal relationship. Although the totality of the data that have been reviewed provides reassurance, pancreatitis will continue to be considered a risk associated with these drugs until more data are available; both agencies continue to investigate this safety signal."[9]

    See also[edit]

    References[edit]

    1. ^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on May 6, 2008. Retrieved September 5, 2008.
  • ^ a b Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (May 2004). "Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes". The Journal of Clinical Endocrinology and Metabolism. 89 (5): 2078–2084. doi:10.1210/jc.2003-031907. PMID 15126524.
  • ^ a b Mentlein R, Gallwitz B, Schmidt WE (June 1993). "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum". European Journal of Biochemistry. 214 (3): 829–835. doi:10.1111/j.1432-1033.1993.tb17986.x. PMID 8100523.
  • ^ Mathieu C, Degrande E (December 2008). "Vildagliptin: a new oral treatment for type 2 diabetes mellitus". Vascular Health and Risk Management. 4 (6): 1349–1360. doi:10.2147/vhrm.s3005. PMC 2663430. PMID 19337548.
  • ^ "EU approves Novartis's Eucreas diabetes drug". Reuters. February 25, 2008.
  • ^ "Galvus" (PDF). www.ema.europa.eu. Retrieved July 29, 2018.
  • ^ Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, et al. (July 2009). "Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin". Diabetes. 58 (7): 1604–1615. doi:10.2337/db09-0058. PMC 2699878. PMID 19403868.
  • ^ Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (July 2013). "Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors". Diabetes. 62 (7): 2595–2604. doi:10.2337/db12-1686. PMC 3712065. PMID 23524641.
  • ^ Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al. (February 2014). "Pancreatic safety of incretin-based drugs--FDA and EMA assessment". The New England Journal of Medicine. 370 (9): 794–797. doi:10.1056/NEJMp1314078. PMID 24571751.
  • External links[edit]


    Retrieved from "https://en.wikipedia.org/w/index.php?title=Vildagliptin&oldid=1229509780"

    Categories: 
    Dipeptidyl peptidase-4 inhibitors
    Pyrrolidines
    Nitriles
    Drugs developed by Novartis
    Carboxamides
    Adamantanes
    Tertiary alcohols
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Drugs with non-standard legal status
    Articles with changed CASNo identifier
    ECHA InfoCard ID from Wikidata
    Drug has EMA link
    Drugboxes which contain changes to verified fields
    Drugboxes which contain changes to watched fields
     



    This page was last edited on 17 June 2024, at 06:01 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki